Egermann M, Lill C A, Griesbeck K, Evans C H, Robbins P D, Schneider E, Baltzer A W
AO Research Institute, Davos, Switzerland.
Gene Ther. 2006 Sep;13(17):1290-9. doi: 10.1038/sj.gt.3302785. Epub 2006 Apr 27.
Critical size defects of bone and delayed fracture healing due to metabolic disorders are still problems in orthopaedic surgery. Adenoviral vectors encoding bone morphogenetic protein-2 (Ad.BMP-2) have been used to stimulate bone formation in small animals. The present study evaluated the use of direct adenoviral gene transfer for inducing bone formation in a large animal. Standardized iliac crest defects were created surgically on both sides of the pelvic bone of white mountain sheep. The efficiency of gene transfer was evaluated using recombinant adenoviruses carrying the cDNA for luciferase. High levels of transgene expression, restricted to the site of injection, were found for the 1st week. Transgene expression then fell considerably, but could still be detected for up to 5 weeks. To investigate the effect on bone healing, Ad.BMP-2 (10(11) particles in 200 mul saline) was unilaterally injected into iliac crest defects and into tibial osteotomies. The contralateral defects remained untreated to evaluate possible systemic effects. The controls were treated with saline solution. Bone formation within the defect, assessed by micro-computed tomography (CT) measurement at 8 weeks, and callus formation after osteotomy were significantly reduced following direct application of Ad.BMP-2. The retardation compared to untreated control animals was additionally found at the contralateral iliac crest indicating a systemic inhibitory effect. Histological analysis confirmed the CT measurement and showed an increased number of inflammatory cells within both defects. Antibodies against the adenovirus and the transgene product were detected in all treated animals. These data show a systemic retardation of bone formation following a single local injection of Ad.BMP-2 in sheep. This finding stands in contrast to the data obtained from small animal models. Further studies are needed to determine the contribution of the immune response to these results, and whether a lower dose of Ad.BMP-2 would be advantageous.
骨的临界尺寸缺损以及代谢紊乱导致的骨折延迟愈合仍是骨科手术中的难题。编码骨形态发生蛋白-2的腺病毒载体(Ad.BMP-2)已被用于刺激小动物的骨形成。本研究评估了直接腺病毒基因转移在大型动物中诱导骨形成的应用。在白山羊骨盆骨两侧通过手术制造标准化的髂嵴缺损。使用携带荧光素酶cDNA的重组腺病毒评估基因转移效率。在第1周发现高水平的转基因表达,且局限于注射部位。随后转基因表达大幅下降,但在长达5周的时间内仍可检测到。为研究对骨愈合的影响,将Ad.BMP-2(200微升盐水中含10¹¹个颗粒)单侧注射到髂嵴缺损处和胫骨截骨处。对侧缺损不进行处理以评估可能的全身效应。对照组用盐溶液处理。在8周时通过微计算机断层扫描(CT)测量评估缺损内的骨形成情况,结果显示直接应用Ad.BMP-2后截骨处的骨痂形成显著减少。与未处理的对照动物相比,在对侧髂嵴也发现了延迟现象,表明存在全身抑制作用。组织学分析证实了CT测量结果,并显示两个缺损内炎性细胞数量增加。在所有处理过的动物中均检测到针对腺病毒和转基因产物的抗体。这些数据表明在绵羊中单次局部注射Ad.BMP-2后骨形成出现全身延迟。这一发现与从小动物模型获得的数据形成对比。需要进一步研究以确定免疫反应对这些结果的影响,以及较低剂量的Ad.BMP-2是否会更具优势。